Shares of Illumina closed yesterday at $182.79 . ILMN has a 1-year high of $213.33 and a 1-year low of $127.69. The stock's 50-day moving average is $193.05 and it's 200-day moving average is $185.96.
On the ratings front, Illumina has been the subject of a number of recent research reports. In a report issued on March 31, BTIG analyst Dane Leone maintained a Buy rating on ILMN, with a price target of $240, which represents a potential upside of 31.3% from where the stock is currently trading. Separately, on February 2, Cantor Fitzgerald's Sung Ji Nam maintained a Hold rating on the stock and has a price target of $166.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Dane Leone and Sung Ji Nam have a total average return of 11.1% and 13.5% respectively. Leone has a success rate of 69.6% and is ranked #990 out of 3568 analysts, while Nam has a success rate of 94.1% and is ranked #470.
In total, one research analyst has assigned a Hold rating and 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $182.79 which is 22.7% above where the stock closed yesterday.
Illumina Inc providessequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response.